| Date Filed | Type | Description |
| 09/26/2023 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Regulation FD Disclosure, Financi...|
Docs:
|
"SECURITIES PURCHASE AGREEMENT",
"EXECUTION VERSION",
"WARRANT NO. ORMP CS-1 TO PURCHASE COMMON STOCK OF SCILEX HOLDING COMPANY",
"WARRANT NO. ORMP CS-2 TO PURCHASE COMMON STOCK OF SCILEX HOLDING COMPANY",
"WARRANT NO. ORMP CS-3 TO PURCHASE COMMON STOCK OF SCILEX HOLDING COMPANY",
"WARRANT NO. ORMP CS-4 TO PURCHASE COMMON STOCK OF SCILEX HOLDING COMPANY",
"WARRANT NO. ORMP CS-5 TO PURCHASE COMMON STOCK OF SCILEX HOLDING COMPANY",
"Scilex Holding Company Specimen Warrant Certificate",
"Capitalized terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms in the Purchase Agreement.",
"Subsidiary Guarantee, by and among Oramed Pharmaceuticals, Acquiom Agency Services LLC, Scilex Holding Company, and certain subsidiaries of Scilex Holding Company party thereto" |
|
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/09/2023 |
8-K
| Acquisition/merger/asset purchase announced |
| 08/07/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 07/13/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/31/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 05/31/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 05/31/2023 |
4
| KIDRON NADAV (President and CEO) has filed a Form 4 on ORAMED PHARMACEUTICALS INC.|
Txns:
| Granted 120,000 shares
@ $0 |
|
| 05/31/2023 |
4
| Kidron Miriam (Chief Scientific Officer) has filed a Form 4 on ORAMED PHARMACEUTICALS INC.|
Txns:
| Granted 53,500 shares
@ $0 |
|
| 05/31/2023 |
4
| Derovan Netanel (Chief Legal Officer) has filed a Form 4 on ORAMED PHARMACEUTICALS INC.|
Txns:
| Granted 20,500 shares
@ $0 |
|
| 05/31/2023 |
4
| Hexter Joshua (COO & CBO) has filed a Form 4 on ORAMED PHARMACEUTICALS INC.|
Txns:
| Granted 27,000 shares
@ $0 |
|
| 05/31/2023 |
4
| Silberman David (CFO) has filed a Form 4 on ORAMED PHARMACEUTICALS INC.|
Txns:
| Granted 24,500 shares
@ $0 |
|
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/01/2023 |
3
| Shapiro Benjamin (Director) has filed a Form 3 on ORAMED PHARMACEUTICALS INC. |
| 05/01/2023 |
8-K
| Quarterly results |
| 04/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/04/2023 |
4
| Mayer Arie (Director) has filed a Form 4 on ORAMED PHARMACEUTICALS INC.|
Txns:
| Bought 5,009 shares
@ $2.22, valued at
$11.1k
Bought 3,800 shares
@ $2.21, valued at
$8.4k
|
|
| 03/16/2023 |
4
| KIDRON NADAV (President and CEO) has filed a Form 4 on ORAMED PHARMACEUTICALS INC.|
Txns:
| Bought 26,000 shares
@ $2.039, valued at
$53k
|
|
| 03/15/2023 |
4
| KIDRON NADAV (President and CEO) has filed a Form 4 on ORAMED PHARMACEUTICALS INC.|
Txns:
| Bought 100,000 shares
@ $2.01, valued at
$201k
|
|
| 03/15/2023 |
4
| Kidron Miriam (Chief Scientific Officer) has filed a Form 4 on ORAMED PHARMACEUTICALS INC.|
Txns:
| Sold 100,000 shares
@ $2.01, valued at
$201k
|
|
| 03/15/2023 |
4
| Rozov Yadin (Director) has filed a Form 4 on ORAMED PHARMACEUTICALS INC.|
Txns:
| Bought 20,000 shares
@ $1.956, valued at
$39.1k
Bought 50,000 shares
@ $2.049, valued at
$102.5k
|
|
| 03/06/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/27/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ...|
Docs:
|
"FOURTH AMENDED AND RESTATED BY-LAWS, ADOPTED EFFECTIVE FEBRUARY 23, 2023",
"ARTICLE XVI 11. The Corporation’ s obligation, if any, to indemnify or to advance expenses to any person serving at its request as a director or officer of another corporation, partnership, joint venture, trust or other enterprise shall be reduced by any amount such person may collect as indemnification or advancement of expenses from such other corporation, partnership, joint venture, trust or other enterprise. 16 ARTICLE XIV FORUM SELECTION 1. Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery and any appellate court thereof shall be the sole and exclusive forum for any derivative action, suit, or proceeding brought on behalf of the Corporation, any action, suit, or proceeding asserting a claim of breach of fiduciary duty owed by an..." |
|
| 01/04/2023 |
4
| Rabinowitz Michael (Chief Commercial Officer) has filed a Form 4 on ORAMED PHARMACEUTICALS INC.|
Txns:
| Sold 1,425 shares
@ $13.0132, valued at
$18.5k
Sold 11,900 shares
@ $12.4917, valued at
$148.7k
|
|
| 12/12/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 11/14/2022 |
8-K
| Quarterly results |
|